Macrophage phenotype and remodeling outcomes in response to biologic scaffolds with and without a cellular component.

Biomaterials
Bryan N BrownStephen F Badylak

Abstract

Recently, macrophages have been characterized as having an M1 or M2 phenotype based on receptor expression, cytokine and effector molecule production, and function. The effects of macrophage phenotype upon tissue remodeling following the implantation of a biomaterial are largely unknown. The objectives of this study were to determine the effects of a cellular component within an implanted extracellular matrix (ECM) scaffold upon macrophage phenotype, and to determine the relationship between macrophage phenotype and tissue remodeling. Partial-thickness defects in the abdominal wall musculature of Sprague-Dawley rats were repaired with autologous body wall tissue, acellular allogeneic rat body wall ECM, xenogeneic pig urinary bladder tissue, or acellular xenogeneic pig urinary bladder ECM. At 3, 7, 14, and 28 days the host tissue response was characterized using histologic, immunohistochemical, and RT-PCR methods. The acellular test articles were shown to elicit a predominantly M2 type response and resulted in constructive remodeling, while those containing a cellular component, even an autologous cellular component, elicited a predominantly M1 type response and resulted in deposition of dense connective tissue and/or scarring. ...Continue Reading

References

Nov 7, 1982·Journal of Theoretical Biology·M J BissellG Parry
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Apr 2, 2002·The Journal of Surgical Research·Stephen BadylakRobert Morff
Jan 30, 2003·Journal of Leukocyte Biology·David M Mosser
Jan 27, 2004·Biomaterials·Donald O FreytesAnn E Rundell
May 26, 2004·Transplant Immunology·Stephen F Badylak
Oct 14, 2004·Annals of Medicine·Søren K Moestrup, Holger J Møller
Nov 9, 2004·Trends in Immunology·Alberto MantovaniMassimo Locati
Jun 1, 2005·The Journal of Surgical Research·Stephen F BadylakAlejandro Nieponice
Oct 18, 2005·Immunity·Alberto MantovaniMassimo Locati
Nov 22, 2005·Clinical and Experimental Immunology·F PorcherayG Gras
Dec 3, 2005·Nature Reviews. Immunology·Siamon Gordon, Philip R Taylor
Mar 8, 2006·Biomaterials·Thomas W GilbertStephen F Badylak
Apr 4, 2006·Tissue Engineering·Bryan BrownStephen F Badylak
Dec 5, 2006·The Journal of Bone and Joint Surgery. American Volume·Jolene E ValentinStephen F Badylak
May 26, 2007·Biomaterials·Stephen F Badylak
Oct 28, 2008·Tissue Engineering. Part a·Stephen F BadylakAnn M Stewart-Akers

❮ Previous
Next ❯

Citations

Jun 15, 2011·Cell and Tissue Research·Neill J Turner, Stephen F Badylak
Nov 20, 2013·Annals of Biomedical Engineering·Eric M SussmanBuddy D Ratner
May 10, 2011·Journal of Materials Science. Materials in Medicine·Likang ChinKathleen A Derwin
May 2, 2009·Journal of Mammary Gland Biology and Neoplasia·Jenifer Monks, Peter M Henson
Jun 29, 2011·Journal of Cardiovascular Translational Research·Elena TousJason A Burdick
May 7, 2013·Biomaterials·Katherine M KuligCraig M Neville
Jan 27, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Carolyn HolladayAbhay Pandit
Dec 8, 2009·Proceedings of the National Academy of Sciences of the United States of America·Vineet AgrawalStephen F Badylak
Aug 11, 2010·Proceedings of the National Academy of Sciences of the United States of America·Lauran R MaddenBuddy D Ratner
Aug 14, 2013·Proceedings of the National Academy of Sciences of the United States of America·Jonathan M FishmanPaolo De Coppi
Jul 30, 2011·Tissue Engineering. Part a·Michelle L ManniThomas W Gilbert
Mar 16, 2012·Tissue Engineering. Part a·Kerry A DalyStephen F Badylak
Feb 15, 2013·Tissue Engineering. Part a·Alexandra BayrakMartina Seifert
Aug 22, 2012·Tissue Engineering. Part a·Brian M SicariStephen F Badylak
Oct 23, 2012·Tissue Engineering. Part B, Reviews·Ming He, Anthony Callanan
Dec 12, 2012·Tissue Engineering. Part B, Reviews·Birgit AndréeAndres Hilfiker
Nov 4, 2010·Tissue Engineering. Part C, Methods·Bryan N BrownStephen F Badylak
Aug 26, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Narutoshi HibinoChristopher K Breuer
Nov 16, 2012·Science Translational Medicine·Anthony AtalaAntonios G Mikos
Oct 26, 2011·Cells, Tissues, Organs·John M WainwrightStephen F Badylak
May 30, 2013·PloS One·Karina H NakayamaAlice F Tarantal
Jan 1, 2012·Journal of Long-term Effects of Medical Implants·Christopher R RowlandFarshid Guilak
Jan 17, 2013·World Journal of Gastroenterology : WJG·Ricardo LondonoStephen F Badylak
Dec 1, 2012·Stem Cells Translational Medicine·David Antonio CantuWeiyuan John Kao
Mar 5, 2014·Biomaterials·Kara L SpillerGordana Vunjak-Novakovic
Jan 1, 2014·Current Urology Reports·Marcus SalvatoriGiuseppe Orlando
Oct 29, 2013·Tissue Engineering. Part a·Bernard GrevemeyerBryan N Brown
Feb 22, 2013·Science Translational Medicine·Sonya B Seif-NaraghiKaren L Christman
Mar 26, 2014·Biomaterials·Virginia BallottaFrank P T Baaijens
Sep 11, 2012·Advanced Drug Delivery Reviews·Ensanya A Abou NeelJung Keun Hyun
Jan 1, 2014·Tissue Engineering. Part a·Alexander Florian ElsaesserNicole Rotter
Jun 18, 2014·Regenerative Medicine·Fanwei MengStephen F Badylak
Apr 15, 2014·Acta Biomaterialia·Bailey V Fearing, Mark E Van Dyke
Apr 17, 2012·Journal of Biomedicine & Biotechnology·Holger KochAndreas Boldt
Sep 25, 2014·BioMed Research International·Silvia BaigueraCostantino Del Gaudio
Aug 21, 2014·Tissue Engineering. Part a·Summer HansonPeiman Hematti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.